Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H17ClN6O2 |
Molecular Weight | 396.83 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CN1C=CC(=N1)C2=CC=C(C#N)C(Cl)=C2)NC(=O)C3=NNC(=C3)C(C)=O
InChI
InChIKey=GMBPVBVTPBWIKC-NSHDSACASA-N
InChI=1S/C19H17ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-/m0/s1
Molecular Formula | C19H17ClN6O2 |
Molecular Weight | 396.83 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26137992
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26137992
ORM-15341 is an active main metabolite of ODM-201, which is structurally distinct from any known antiandrogens including the second-generation antiandrogens enzalutamide. ORM-15341 is a potent and full antagonist for human androgen receptor. It was shown, that in VCaP prostate cancer cells containing endogenous AR gene amplification and overexpressing AR, ORM-15341 inhibited cell proliferation more efficiently than enzalutamide or ARN-509.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26313416
Curator's Comment: Known to be CNS non-penetrant in mouse. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26137992 |
38.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26313416
HepaRG cells were treated with 10 μM of ORM-15341
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:21:25 GMT 2023
by
admin
on
Sat Dec 16 11:21:25 GMT 2023
|
Record UNII |
9EPS75QMTL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID101111196
Created by
admin on Sat Dec 16 11:21:25 GMT 2023 , Edited by admin on Sat Dec 16 11:21:25 GMT 2023
|
PRIMARY | |||
|
9EPS75QMTL
Created by
admin on Sat Dec 16 11:21:25 GMT 2023 , Edited by admin on Sat Dec 16 11:21:25 GMT 2023
|
PRIMARY | |||
|
52919826
Created by
admin on Sat Dec 16 11:21:25 GMT 2023 , Edited by admin on Sat Dec 16 11:21:25 GMT 2023
|
PRIMARY | |||
|
1297537-33-7
Created by
admin on Sat Dec 16 11:21:25 GMT 2023 , Edited by admin on Sat Dec 16 11:21:25 GMT 2023
|
PRIMARY | |||
|
DB15647
Created by
admin on Sat Dec 16 11:21:25 GMT 2023 , Edited by admin on Sat Dec 16 11:21:25 GMT 2023
|
PRIMARY | |||
|
Ketodarolutamide
Created by
admin on Sat Dec 16 11:21:25 GMT 2023 , Edited by admin on Sat Dec 16 11:21:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |